UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

(Check one):

OMB APPROVAL
  OMB Number: 3235-0058
Expires: May 31, 2012
Estimated average burden
hours per response .... 2.50
   
   
   
   

[             ] Form 10-K    [             ] Form 20-F    [             ] Form 11-K
[ x ] Form 10-Q    [             ] Form 10-D    [             ] Form N-SAR    [             ] Form N-CSR

For Period Ended: September 30, 2011

[             ] Transition Report on Form 10-K
[             ] Transition Report on Form 20-F
[             ] Transition Report on Form 11-K
[             ] Transition Report on Form 10-Q
[             ] Transition Report on Form N-SAR

For the Transition Period Ended:

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
Not Applicable

PART I — REGISTRANT INFORMATION

MabCure Inc.
Full Name of Registrant

N/A
Former Name if Applicable

760 Parkside Avenue # 208, Brooklyn,
Address of Principal Executive Office (Street and Number)

NY 11226
City, State and Zip Code

PART II — RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

x (a) The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
     
x (b)
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
     
  (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III — NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q,10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

MabCure Inc. (the "Company") could not complete the filing of its Quarterly Report on Form 10-Q for the fiscal period ended September 30, 2011 due to a delay in the compilation and review of the information to be included in the Company's Quarterly Report on Form 10-Q, which delay could not be eliminated by the Company without unreasonable effort and expense. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, as amended, the Company will file its Form 10-Q no later than the fifth calendar day following the prescribed due date.

PART IV — OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

  Dr. Amnon Gonenne 914 595-6342
  (Name) (Area Code) (Telephone Number)

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed ? If answer is no, identify report(s).

[ x ] Yes [             ] No

   
(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof ?

[             ] Yes [ x ] No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

MABCURE INC.
(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 14, 2011 By: /s/ Dr. Amnon Gonenne
    Dr. Amnon Gonenne
  Title: President and Chief Executive Officer

MabCure (CE) (USOTC:MBCI)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas MabCure (CE).
MabCure (CE) (USOTC:MBCI)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas MabCure (CE).